PET-adapted sequential salvage therapy with brentuximab vedotin followed by augmented ifosamide, carboplatin, and etoposide for patients with relapsed and refractory Hodgkin's lymphoma: A non-randomised, open-label, single-centre, phase 2 study Journal Article


Authors: Moskowitz, A. J.; Schöder, H.; Yahalom, J.; Mccall, S. J.; Fox, S. Y.; Gerecitano, J.; Grewal, R.; Hamlin, P. A.; Horwitz, S.; Kobos, R.; Kumar, A.; Matasar, M.; Noy, A.; Palomba, M. L.; Perales, M. A.; Portlock, C. S.; Sauter, C.; Shukla, N.; Steinherz, P.; Straus, D.; Trippett, T.; Younes, A.; Zelenetz, A.; Moskowitz, C. H.
Article Title: PET-adapted sequential salvage therapy with brentuximab vedotin followed by augmented ifosamide, carboplatin, and etoposide for patients with relapsed and refractory Hodgkin's lymphoma: A non-randomised, open-label, single-centre, phase 2 study
Abstract: Background: Pre-transplantation 18F-fluorodeoxyglucose (FDG) PET-negativity is one of the strongest predictors of outcome after high-dose therapy and autologous stem-cell transplant (HDT/ASCT) for patients with relapsed or refractory Hodgkin's lymphoma. In this study, we assessed the feasibility and activity of PET-adapted salvage therapy with brentuximab vedotin, followed by augmented ifosfamide, carboplatin, and etoposide (ICE). Methods: In this non-randomised, open-label, single-centre, phase 2 trial, we enrolled patients with relapsed or refractory Hodgkin's lymphoma who had failed one previous doxorubicin-containing chemotherapy regimen. All patients received weekly infusions of 1·2 mg/kg brentuximab vedotin on days 1, 8, and 15 for two 28 day cycles. After completion of brentuximab vedotin treatment, patients received a PET scan. Patients who achieved PET-negative status (a Deauville score of 1 or 2) proceeded directly to HDT/ASCT; those with persistent abnormalities on PET received two cycles of augmented ICE (augICE; two doses of ifosfamide 5000 mg/m2 in combination with mesna 5000 mg/m2 continuous infusion over 24 h, days 1 and 2; one dose of carboplatin AUC 5, day 3; three doses of etoposide 200 mg/m2 every 12 h, day 1) before consideration for HDT/ASCT. Only patients with persistent abnormalities on PET after brentuximab vedotin received augICE; however, all patients in the intention-to-treat population were assessed for the primary outcome, which was the proportion of patients who were PET-negative after brentuximab vedotin alone or brentuximab vedotin followed by augICE. This study is registered with ClinicalTrials.gov, number NCT01508312, and is no longer accruing patients. Findings: Between Jan 5, 2012, and Oct 4, 2013, we enrolled 46 patients. One patient was deemed ineligible, and not evaluable, before treatment initiation owing to having nodular, lymphocyte-predominant Hodgkin's lymphoma and thus 45 patients received treatment. After brentuximab vedotin, 12 patients (27%, 95% CI 13-40) were PET-negative and proceeded to HDT/ASCT. 33 (73%, 95% CI 60-86) patients were PET-positive after brentuximab vedotin; one PET-positive patient withdrew consent, therefore 32 PET-positive patients received augICE, 22 (69%, 95% CI 53-85) of whom were PET-negative. Overall, 34 patients (76%, 95% CI 62-89) achieved PET-negativity. All 44 patients who completed treatment as per protocol proceeded to receive HDT/ASCT. Brentuximab vedotin was well tolerated and associated with few grade 3-4 adverse events including hyperglycaemia (two [4%] patients, grade 3), nausea (one [2%], grade 3), hypoglycaemia (one [2%], grade 3 and one [2%], grade 4), and hypocalcaemia (one [2%], grade 3 and one [2%], grade 4). Interpretation: PET-adapted sequential salvage therapy with brentuximab vedotin followed by augICE resulted in a high proportion of patients with relapsed or refractory Hodgkin's lymphoma achieving PET-negativity, and therefore could optimise the chance of cure after HDT/ASCT. Funding: Seattle Genetics. © 2015 Elsevier Ltd.
Keywords: adolescent; adult; clinical article; aged; prednisone; constipation; drug tolerability; neutropenia; cancer recurrence; salvage therapy; doxorubicin; diarrhea; drug dose reduction; cancer radiotherapy; cytarabine; rituximab; cancer staging; positron emission tomography; carboplatin; dacarbazine; multiple cycle treatment; phase 2 clinical trial; sensory neuropathy; etoposide; leukopenia; nausea; neuropathy; thrombocytopenia; vomiting; myalgia; cyclophosphamide; melphalan; vincristine; autologous stem cell transplantation; continuous infusion; carmustine; chlormethine; ifosfamide; procarbazine; vinblastine; hodgkin disease; arthralgia; coughing; dyspnea; febrile neutropenia; hyperglycemia; hypomagnesemia; pruritus; rash; drug fatality; feasibility study; add on therapy; radiation dose fractionation; fluorodeoxyglucose f 18; bleomycin; hypoglycemia; progressive multifocal leukoencephalopathy; mesna; alopecia; plerixafor; skin infection; hypocalcemia; filgrastim; anorectal disease; brentuximab vedotin; intention to treat analysis; human; male; female; priority journal; article
Journal Title: Lancet Oncology
Volume: 16
Issue: 3
ISSN: 1470-2045
Publisher: Elsevier Science, Inc.  
Date Published: 2015-03-01
Start Page: 284
End Page: 292
Language: English
DOI: 10.1016/s1470-2045(15)70013-6
PROVIDER: scopus
PUBMED: 25683846
DOI/URL:
Notes: Export Date: 2 April 2015 -- Source: Scopus
Altmetric Score
MSK Authors
  1. Joachim Yahalom
    395 Yahalom
  2. Carol Portlock
    178 Portlock
  3. Craig Moskowitz
    372 Moskowitz
  4. Ariela Noy
    205 Noy
  5. Maria Lia Palomba
    121 Palomba
  6. Steven M Horwitz
    351 Horwitz
  7. Ravinder K Grewal
    57 Grewal
  8. Heiko Schoder
    285 Schoder
  9. Craig Steven Sauter
    158 Sauter
  10. Andrew D Zelenetz
    550 Zelenetz
  11. Miguel-Angel Perales
    365 Perales
  12. Alison Moskowitz
    141 Moskowitz
  13. Paul Hamlin
    170 Hamlin
  14. Matthew J Matasar
    119 Matasar
  15. David J Straus
    205 Straus
  16. Peter G Steinherz
    164 Steinherz
  17. Susan J McCall
    14 McCall
  18. Rachel Kobos
    65 Kobos
  19. Neerav Shukla
    69 Shukla
  20. Anita Kumar
    51 Kumar
  21. Anas Younes
    195 Younes
  22. Stephanie Yvonne Fox
    5 Fox